GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Wuxi AppTec Co Ltd (SHSE:603259) » Definitions » EV-to-EBITDA

Wuxi AppTec Co (SHSE:603259) EV-to-EBITDA

: 9.55 (As of Today)
View and export this data going back to 2018. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Wuxi AppTec Co's enterprise value is ¥114,880 Mil. Wuxi AppTec Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ¥12,026 Mil. Therefore, Wuxi AppTec Co's EV-to-EBITDA for today is 9.55.

The historical rank and industry rank for Wuxi AppTec Co's EV-to-EBITDA or its related term are showing as below:

SHSE:603259' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.88   Med: 49.15   Max: 122.44
Current: 9.2

During the past 10 years, the highest EV-to-EBITDA of Wuxi AppTec Co was 122.44. The lowest was 8.88. And the median was 49.15.

SHSE:603259's EV-to-EBITDA is ranked better than
69.75% of 119 companies
in the Medical Diagnostics & Research industry
Industry Median: 15.33 vs SHSE:603259: 9.20

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-19), Wuxi AppTec Co's stock price is ¥42.20. Wuxi AppTec Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ¥3.240. Therefore, Wuxi AppTec Co's PE Ratio for today is 13.02.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Wuxi AppTec Co EV-to-EBITDA Historical Data

The historical data trend for Wuxi AppTec Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuxi AppTec Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.66 69.74 46.61 19.08 14.56

Wuxi AppTec Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.08 20.31 15.54 21.20 14.56

Competitive Comparison

For the Diagnostics & Research subindustry, Wuxi AppTec Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuxi AppTec Co EV-to-EBITDA Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Wuxi AppTec Co's EV-to-EBITDA falls into.



Wuxi AppTec Co EV-to-EBITDA Calculation

Wuxi AppTec Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=114880.182/12025.572
=9.55

Wuxi AppTec Co's current Enterprise Value is ¥114,880 Mil.
Wuxi AppTec Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥12,026 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuxi AppTec Co  (SHSE:603259) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Wuxi AppTec Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=42.20/3.240
=13.02

Wuxi AppTec Co's share price for today is ¥42.20.
Wuxi AppTec Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3.240.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Wuxi AppTec Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Wuxi AppTec Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuxi AppTec Co (SHSE:603259) Business Description

Traded in Other Exchanges
Address
288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, CHN, 200131
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services through the discovery, development, and manufacturing spectrum for small-molecule drugs, cell therapies, and gene therapies as well as providing testing services for medical devices. Its segments comprise China-based laboratory services; U.S.-based laboratory services; Clinical research and other CRO services; CDMO services; and Others. The majority of revenue gets derived from China-based laboratory services that include small molecules discovery, such as synthetic chemistry, medicinal chemistry, analytical chemistry, biology, drug metabolism and pharmacokinetics (DMPK)/absorption, distribution, metabolism, and excretion (ADME), toxicology and bioanalytical services.

Wuxi AppTec Co (SHSE:603259) Headlines

No Headlines